+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Breast Cancer Diagnostics Market Research Report by Type, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 5206469
  • Report
  • July 2021
  • Region: Global
  • 193 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Breast Cancer Diagnostics Market will Grow to USD 8,337.08 Million by 2026, at a CAGR of 7.88%

FEATURED COMPANIES

  • Abbott Laboratories
  • Biocept, Inc.
  • C.R. Bard, Inc.
  • F. Hoffmann-La Roche Ltd
  • Hologic Inc.
  • Leica Biosystems
  • MORE
The Global Breast Cancer Diagnostics Market size was estimated at USD 5,286.71 Million in 2020 and expected to reach USD 5,685.81 Million in 2021, at a Compound Annual Growth Rate (CAGR) 7.88% to reach USD 8,337.08 Million by 2026.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Breast Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Type, the Breast Cancer Diagnostics Market was studied across Biopsy, Blood Tests, Genomic Tests, and Imaging.
  • Based on Technique, the Breast Cancer Diagnostics Market was studied across Imaging, Molecular Testing, and Tissue Biopsy Tests. The Imaging is further studied across Analog Mammography, Breast Ultrasound System, Digital Mammography, Mammography, MRI Scan, and PET/CT Scan.
  • Based on End-user, the Breast Cancer Diagnostics Market was studied across Diagnostic Laboratories, Hospitals & Ambulatory Surgery Center, and Research & Academic Institutes.
  • Based on Region, the Breast Cancer Diagnostics Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Breast Cancer Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Breast Cancer Diagnostics Market, including Abbott Laboratories, Agilent Technologies, Inc., Ascenda BioSciences LLC, AstraZeneca, PLC, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc, Biocept, Inc., BioNTech SE, C.R. Bard, Inc., Danaher Corporation, Epigenomics Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corporation, GE Healthcare, Genomic Health, Hologic Inc., Illumina, Inc., Koninklijke Philips N.V., Leica Biosystems, Myriad Genetics, Inc., NanoString Technologies, Inc, Paragon Biosciences LLC, Questex LLC, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Todos Medical, and Toshiba Corporation.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Breast Cancer Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Breast Cancer Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Breast Cancer Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Breast Cancer Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Breast Cancer Diagnostics Market?
6. What is the market share of the leading vendors in the Global Breast Cancer Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Breast Cancer Diagnostics Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Biocept, Inc.
  • C.R. Bard, Inc.
  • F. Hoffmann-La Roche Ltd
  • Hologic Inc.
  • Leica Biosystems
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Type Outlook
3.4. Technique Outlook
3.5. End-user Outlook
3.6. Region Outlook
3.7. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of breast cancer
5.1.1.2. Favourable reimbursement framework for breast cancer diagnosis
5.1.1.3. Growing number of breast cancer screening programs
5.1.2. Restraints
5.1.2.1. Dearth of the skilled and trained professionals
5.1.3. Opportunities
5.1.3.1. Technological advancements such as introduction of hybrid imaging technique
5.1.3.2. Focus on development of effective diagnostic
5.1.4. Challenges
5.1.4.1. Ignorance of the prediagnostic symptoms
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Breast Cancer Diagnostics Market, by Type
6.1. Introduction
6.2. Biopsy
6.3. Blood Tests
6.4. Genomic Tests
6.5. Imaging

7. Breast Cancer Diagnostics Market, by Technique
7.1. Introduction
7.2. Imaging
7.2.1. Analog Mammography
7.2.2. Breast Ultrasound System
7.2.3. Digital Mammography
7.2.4. Mammography
7.2.5. MRI Scan
7.2.6. PET/CT Scan
7.3. Molecular Testing
7.4. Tissue Biopsy Tests

8. Breast Cancer Diagnostics Market, by End-user
8.1. Introduction
8.2. Diagnostic Laboratories
8.3. Hospitals & Ambulatory Surgery Center
8.4. Research & Academic Institutes

9. Americas Breast Cancer Diagnostics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Breast Cancer Diagnostics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Thailand

11. Europe, Middle East & Africa Breast Cancer Diagnostics Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Abbott Laboratories
13.2. Agilent Technologies, Inc.
13.3. Ascenda BioSciences LLC
13.4. AstraZeneca, PLC
13.5. Becton, Dickinson, and Company
13.6. Bio-Rad Laboratories, Inc
13.7. Biocept, Inc.
13.8. BioNTech SE
13.9. C.R. Bard, Inc.
13.10. Danaher Corporation
13.11. Epigenomics Inc
13.12. F. Hoffmann-La Roche Ltd
13.13. FUJIFILM Holdings Corporation
13.14. GE Healthcare
13.15. Genomic Health
13.16. Hologic Inc.
13.17. Illumina, Inc.
13.18. Koninklijke Philips N.V.
13.19. Leica Biosystems
13.20. Myriad Genetics, Inc.
13.21. NanoString Technologies, Inc
13.22. Paragon Biosciences LLC
13.23. Questex LLC
13.24. Siemens Healthineers AG
13.25. Thermo Fisher Scientific Inc.
13.26. Todos Medical
13.27. Toshiba Corporation

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2020 (USD MILLION)
FIGURE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2020 (USD MILLION)
FIGURE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2020 (USD MILLION)
FIGURE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2020 (USD MILLION)
FIGURE 6. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: MARKET DYNAMICS
FIGURE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
FIGURE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2020 VS 2026 (USD MILLION)
FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2026
FIGURE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2026 (USD MILLION)
FIGURE 13. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 14. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, 2018-2026 (USD MILLION)
FIGURE 15. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 16. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC TESTS, 2018-2026 (USD MILLION)
FIGURE 17. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC TESTS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 18. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2026 (USD MILLION)
FIGURE 19. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 20. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2020 VS 2026 (%)
FIGURE 21. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2020 VS 2026 (USD MILLION)
FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2026
FIGURE 23. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2026 (USD MILLION)
FIGURE 24. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 25. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ANALOG MAMMOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 26. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ANALOG MAMMOGRAPHY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 27. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BREAST ULTRASOUND SYSTEM, 2018-2026 (USD MILLION)
FIGURE 28. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BREAST ULTRASOUND SYSTEM, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 29. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL MAMMOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 30. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL MAMMOGRAPHY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 31. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 32. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 33. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI SCAN, 2018-2026 (USD MILLION)
FIGURE 34. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI SCAN, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 35. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PET/CT SCAN, 2018-2026 (USD MILLION)
FIGURE 36. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PET/CT SCAN, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 37. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTING, 2018-2026 (USD MILLION)
FIGURE 38. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 39. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY TESTS, 2018-2026 (USD MILLION)
FIGURE 40. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY TESTS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 41. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2020 VS 2026 (%)
FIGURE 42. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2020 VS 2026 (USD MILLION)
FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2026
FIGURE 44. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2026 (USD MILLION)
FIGURE 45. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 46. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & AMBULATORY SURGERY CENTER, 2018-2026 (USD MILLION)
FIGURE 47. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & AMBULATORY SURGERY CENTER, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 48. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2026 (USD MILLION)
FIGURE 49. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 50. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 51. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 52. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 53. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 54. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 55. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 56. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 57. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 58. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 59. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 60. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 61. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 62. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 63. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 64. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 65. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 66. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 67. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 68. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 69. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 70. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 71. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 72. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 73. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 74. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 75. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 76. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 77. UNITED ARAB EMIRATES BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 78. UNITED KINGDOM BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 79. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX
FIGURE 80. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 81. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2026 (USD MILLION)
TABLE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC TESTS, BY REGION, 2018-2026 (USD MILLION)
TABLE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2026 (USD MILLION)
TABLE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2026 (USD MILLION)
TABLE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ANALOG MAMMOGRAPHY, BY REGION, 2018-2026 (USD MILLION)
TABLE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BREAST ULTRASOUND SYSTEM, BY REGION, 2018-2026 (USD MILLION)
TABLE 13. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL MAMMOGRAPHY, BY REGION, 2018-2026 (USD MILLION)
TABLE 14. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2018-2026 (USD MILLION)
TABLE 15. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI SCAN, BY REGION, 2018-2026 (USD MILLION)
TABLE 16. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PET/CT SCAN, BY REGION, 2018-2026 (USD MILLION)
TABLE 17. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2026 (USD MILLION)
TABLE 18. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY TESTS, BY REGION, 2018-2026 (USD MILLION)
TABLE 19. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 20. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2026 (USD MILLION)
TABLE 21. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & AMBULATORY SURGERY CENTER, BY REGION, 2018-2026 (USD MILLION)
TABLE 22. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2026 (USD MILLION)
TABLE 23. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 24. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 25. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 26. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 27. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 28. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 29. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 30. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 31. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 32. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 33. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 34. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 35. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 36. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 37. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 38. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 39. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 40. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 41. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 42. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 43. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 44. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 45. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 46. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 47. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 48. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 49. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 50. UNITED ARAB EMIRATES BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 51. UNITED KINGDOM BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 52. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: SCORES
TABLE 53. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: BUSINESS STRATEGY
TABLE 54. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: PRODUCT SATISFACTION
TABLE 55. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: RANKING
TABLE 56. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 57. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: MERGER & ACQUISITION
TABLE 58. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 59. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 60. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: INVESTMENT & FUNDING
TABLE 61. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 62. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Ascenda BioSciences LLC
  • AstraZeneca, PLC
  • Becton, Dickinson, and Company
  • Bio-Rad Laboratories, Inc
  • Biocept, Inc.
  • BioNTech SE
  • C.R. Bard, Inc.
  • Danaher Corporation
  • Epigenomics Inc
  • F. Hoffmann-La Roche Ltd
  • FUJIFILM Holdings Corporation
  • GE Healthcare
  • Genomic Health
  • Hologic Inc.
  • Illumina, Inc.
  • Koninklijke Philips N.V.
  • Leica Biosystems
  • Myriad Genetics, Inc.
  • NanoString Technologies, Inc
  • Paragon Biosciences LLC
  • Questex LLC
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Todos Medical
  • Toshiba Corporation
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll